CHAPEL HILL

The Coca-Cola Company Announces Election of Corporate Officers and Declares Regular Quarterly Dividend

Retrieved on: 
Thursday, May 2, 2024
Packaging, Retail, Restaurant, Bar, Other Retail, Manufacturing, Other Manufacturing, Food, Beverage, Financial management, Supply, University, LLP, Certification, Economics, Hillsdale College, Columbia University, Research, The Coca-Cola Company, CPA, Toronto Metropolitan University, Ford Motor Company, IMD, Institute of Management Accountants, PwC, Coca-Cola, Multimedia, BP, MBA, Ernst & Young, Honeywell, Strategic planning, Management

The Board of Directors of The Coca-Cola Company today announced the election of corporate officers, along with declaring the company’s regular quarterly dividend.

Key Points: 
  • The Board of Directors of The Coca-Cola Company today announced the election of corporate officers, along with declaring the company’s regular quarterly dividend.
  • View the full release here: https://www.businesswire.com/news/home/20240502638667/en/
    Brenda Hofmann was elected senior vice president and chief of internal audit, effective Aug. 1.
  • She went on to hold numerous roles in finance, procurement and general management, including investor relations, strategic planning and commercial finance.
  • The company today declared a regular quarterly dividend of 48.5 cents per common share, payable July 1 to shareowners of record of the company as of the close of business June 14.

Civil Engineering Luminary Bill Derks Announces Retirement from McAdams

Retrieved on: 
Thursday, May 2, 2024
RTP, HUB, Land development, Research Triangle Park, Kenyon College, Water resources, Transport, Engineering, Retirement, Pressure, Triangle, Growth, Management

RALEIGH, N.C., May 2, 2024 /PRNewswire/ -- McAdams, the Raleigh–based multidisciplinary design and engineering firm known for its expertise in civil / site design, land planning, landscape architecture, transportation, water resources, and geomatics, has announced the retirement of Bill Derks, Vice President of Land Development. Derks, who started with the firm in August 1996, has been instrumental in advancing some of the most significant development projects in the Raleigh-Durham area. His retirement on May 1, 2024, marks the culmination of a remarkable career at McAdams, capping a nearly 30-year tenure with the company.

Key Points: 
  • Bill Derks, Esteemed Civil Engineer Since 1996, to Conclude Storied 27-Year Career at McAdams in May 2024
    RALEIGH, N.C., May 2, 2024 /PRNewswire/ -- McAdams , the Raleigh–based multidisciplinary design and engineering firm known for its expertise in civil / site design, land planning, landscape architecture, transportation, water resources, and geomatics, has announced the retirement of Bill Derks, Vice President of Land Development.
  • His retirement on May 1, 2024, marks the culmination of a remarkable career at McAdams, capping a nearly 30-year tenure with the company.
  • Derks, who made a transition from business management and marketing to civil engineering, is revered for combining creative insight with analytical skills.
  • McAdams continues its commitment to maintaining the standards of quality and excellence that Bill Derks so perfectly embodied and helped establish throughout the team.

Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer

Retrieved on: 
Monday, April 15, 2024
University, GSK plc, Reata Pharmaceuticals, Novartis, Genentech, Doctor of Philosophy, Disease, GSK, Patient, Acquisition, Marketing, MBA, BBA, Biogen, Therapy, Galderma, Pharmaceutical industry

Mr. Hooks joins Applied with over 30 years of biopharmaceutical experience in rare disease marketing and sales, holding various leadership roles.

Key Points: 
  • Mr. Hooks joins Applied with over 30 years of biopharmaceutical experience in rare disease marketing and sales, holding various leadership roles.
  • Mr. Hooks will be responsible for leading Applied’s commercial preparations for the potential launch of govorestat for the treatment of Classic Galactosemia and SORD.
  • “I am pleased to welcome Dale to Applied, particularly at this critical stage in the company’s lifecycle as we approach the govorestat potential approval and launch,” said Shoshana Shendelman, PhD, Founder and CEO of Applied Therapeutics.
  • “I am excited to join Applied Therapeutics as the company nears significant and transformative milestones,” said Mr. Hooks.

Modern Health Welcomes Dr. Reena Pande and Dr. Samantha Meltzer-Brody As Clinical Advisors

Retrieved on: 
Monday, April 29, 2024
Mental Health, Business, Health, Professional Services, Human Resources, Well, School, FDA, Physical, University, Address space, Elevate, Learning, Psychiatry, PPD, Public health, Clinical research, MOMS, Trial of the century, Parent, Data science, Exercise, Mental health, MPH, Acquisition, Circle, Harvard Medical School, Master, Anxiety, Mental, Harvard University, Organization, Prevalence, Nursing

Modern Health , a leading global workplace mental health platform, today announces the appointment of Samantha Meltzer-Brody, MD, MPH , as Clinical Advisor and Board member of Modern Health’s Professional Corporation entities, and Reena Pande, MD MSc , as Clinical Advisor.

Key Points: 
  • Modern Health , a leading global workplace mental health platform, today announces the appointment of Samantha Meltzer-Brody, MD, MPH , as Clinical Advisor and Board member of Modern Health’s Professional Corporation entities, and Reena Pande, MD MSc , as Clinical Advisor.
  • "We are incredibly honored to welcome esteemed clinical advisors like Dr. Pande and Dr. Meltzer-Brody to our team.
  • I have been impressed with how Modern Health is redefining global workplace well-being,” comments Dr. Samantha Meltzer-Brody, Clinical Advisor at Modern Health.
  • These exciting findings support the clinical effectiveness and sustainability of the Modern Health platform for improving and preserving mental health and reinforce the utility of digitally delivered mental health services.

Immunome Appoints Sandra M. Swain to Board of Directors

Retrieved on: 
Thursday, April 25, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Health Technology, MedStar Health, University, Bangladesh Technical Education Board, Pfizer, Genetic distance, Professor, Vanderbilt University, Doctor of Philosophy, National Cancer Institute, Dean (education), IND, ASCO, Patient, National Institutes of Health, Society, Acquisition, Executive Committee, Georgetown University Medical Center, Internal medicine, Investigational New Drug

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D., to its Board of Directors.

Key Points: 
  • Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D., to its Board of Directors.
  • “Immunome is pleased to welcome Sandra to the Board of Directors, especially given her extensive experience as a successful clinical researcher,” stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome.
  • Dr. Swain served on the board of directors of the American Society of Clinical Oncology (ASCO) from 2008-2013 and was ASCO President 2012-13.
  • Dr. Swain previously served on the board of directors of Seagen Inc. from November 2022 until its acquisition by Pfizer Inc. in December 2023.

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference

Retrieved on: 
Tuesday, April 16, 2024
Biotechnology, Pharmaceutical, Health, Cardiology, Rationale, University, Idiopathic pulmonary fibrosis, ATSF, ATS, Pulmonary hypertension, Route of administration, High Risk, PAH, Conference, Research, Electronic health record, Idiopathic disease, Orthostatic hypertension, University of North Carolina, Intelligence, Data, Pulmonary fibrosis, UTHR, Treatment, Doctor of Pharmacy, Inova Fairfax Hospital, University of Lagos, Prevalence, University of Florida, Creativity, American Thoracic Society, Medicine, PBC, Therapy, Theme, Incident, Pharmaceutical industry

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Diego on May 17-22, 2024.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Diego on May 17-22, 2024.
  • At ATS, United Therapeutics will host an educational industry theater on implementing treprostinil induction strategies in pulmonary hypertension, and the company is sponsoring the ATS 2024 Women’s Forum.
  • “We look forward to presenting the latest data on several of our key products and development programs,” said Andrew Nelsen, PharmD, Vice President, Global Medical Affairs at United Therapeutics.
  • We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC).

Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year

Retrieved on: 
Wednesday, April 10, 2024
Research, Genetics, Clinical Trials, Biotechnology, Other Health, Managed Care, Health, Science, Oncology, University, MBA, CFOS, Growth, Management

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that, for the second year in a row, its chief financial officer, Frank Stokes, has been selected as a Top 25 CFO of Houston by TOP CFOs (formerly Finance & Investing).

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that, for the second year in a row, its chief financial officer, Frank Stokes, has been selected as a Top 25 CFO of Houston by TOP CFOs (formerly Finance & Investing).
  • The annual award recognizes the top-performing CFOs by region, selected for their skills in leading complex financial departments and their ability to drive growth and profitability as influential financial leaders in their communities.
  • “I am proud of Frank for earning a second placement among Houston’s Top 25 CFOs,” said Derek Maetzold, president and chief executive officer at Castle Biosciences.
  • “In a city as dynamic and competitive as Houston, this recognition is a testament to Frank’s financial leadership in the growth and development of our company.”
    Stokes has served as Castle’s chief financial officer since December 2017.

Early Check Newborn Screening Study Taps Revvity to Provide Genome Sequencing

Retrieved on: 
Thursday, April 25, 2024
University, Risk, Public health, Health, FACMG, Partnership, Parent, Research, Workflow, RTI International, NGS, Medicine, SVP, Therapy, Genetic counseling, Organization, Gene, RTI, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C. and WALTHAM, Mass., April 25, 2024 /PRNewswire/ -- RTI International today announced that Early Check, a groundbreaking research study that provides free voluntary health tests for newborns up to four weeks old in North Carolina, has chosen Revvity, Inc. to conduct genome sequencing for the study starting in May.

Key Points: 
  • The agreement with Revvity will allow Early Check to continue to test newborns for hundreds of childhood-onset rare genetic conditions , many of which are not included in North Carolina's standard newborn screening, as the study assesses critical questions about when and how to integrate genome sequencing into universal newborn screening.
  • "Revvity has a proven track record in newborn screening and conducting sequencing with accuracy and efficiency, which are critical to the success of this research study."
  • Revvity's genome sequencing workflow is powered by the AVITI™ System , an innovative and emerging genome sequencing platform developed by Revvity's partner Element Biosciences, Inc. Revvity's workflow includes sample-to-answer that saves time and effort required for genomic sample analysis.
  • Early Check began offering genome sequencing in September 2023 .

H/K/B Cosmetic Surgery is one of the Top 10 ellacor Procedure Providers

Retrieved on: 
Wednesday, April 17, 2024
Neck, Face, Abdomen, Patient, Triangle, Skin

CHARLOTTE, N.C., April 17, 2024 /PRNewswire/ -- H/K/B Cosmetic Surgery is proud to announce its recognition as one of the Top 25 ellacor Procedure Providers in the nation by Cytrellis.

Key Points: 
  • CHARLOTTE, N.C., April 17, 2024 /PRNewswire/ -- H/K/B Cosmetic Surgery is proud to announce its recognition as one of the Top 25 ellacor Procedure Providers in the nation by Cytrellis.
  • H/K/B Cosmetic Surgery is dedicated to exceeding patient expectations and achieving best-in-class results.
  • Ellacor is a revolutionary treatment that sets a new standard in non-surgical facial rejuvenation to remove wrinkles and excess skin.
  • "Ellacor has been a valuable tool for our patients at H/K/B Cosmetic Surgery.

NYU Langone Health's New Optimal Aging Institute to Further Explore the Link Between Vascular Health and Aging

Retrieved on: 
Thursday, April 11, 2024
Kidney disease, Mayo Clinic, Protein, Risk, Blood, Research, Doctor of Philosophy, Cognition, NYU, Life, Lung, Biomarker, Sleep, Population health, Vascular disease, NINDS, NYU Langone Health, University of Texas System, Alzheimer's disease, Baylor College of Medicine, Dementia, University of Minnesota, Ageing, SDOH, Johns Hopkins University, Huber loss, NIH, Amnesia, Publication, Tissue, Heart, MIND, Female, Multimorbidity, Clinical trial, University, Bangladesh Technical Education Board, DSM-IV codes, Notifiable disease, Policy, Frailty, MD, ARIC, Atherosclerosis, Disease, Hypertension, Community, Pharmaceutical industry

NEW YORK, April 11, 2024 /PRNewswire/ -- Researchers at the newly-formed Optimal Aging Institute at NYU Langone Health have been awarded $31 million by the National Institutes of Health (NIH) for a diverse, ten university cohort to study how vascular risk factors contribute to dementia and other age-related disorders in those over the age of 85, building upon existing research.

Key Points: 
  • Close integration with partners across NYU Langone Health system, Coresh said, enables the Institute to implement and test interventions with real-world impacts in real-time, advancing practice-changing research to improve outcomes for all.
  • to highlight an important topic at the intersection of vascular health and aging.
  • The event, co-sponsored by NYU Langone's Department of Population Health and the Optimal Aging Institute, will feature six renowned experts in the field and will showcase recent groundbreaking research on how treating hypertension may prevent dementia.
  • The research is supported by The National Heart, Lung, and Blood Institute, a division of the NIH, grant number U01HL096812.